ImmunityBio, Inc.
IBRX
$7.82
-$0.24-2.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 91.79% | 167.53% | 431.11% | 433.76% | 2,568.79% |
| Total Other Revenue | 14,100.00% | 387.50% | -96.24% | 84.87% | -92.98% |
| Total Revenue | 93.91% | 167.64% | 406.95% | 425.07% | 2,423.88% |
| Cost of Revenue | 119.12% | 310.34% | -- | -- | -- |
| Gross Profit | 93.78% | 167.14% | 401.89% | 422.17% | 2,410.89% |
| SG&A Expenses | 22.40% | 40.17% | -7.83% | 0.99% | -15.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.58% | 40.83% | 33.81% | 1.54% | -2.66% |
| Operating Income | 13.45% | -8.32% | 6.80% | 30.68% | 28.24% |
| Income Before Tax | -149.60% | -387.13% | -4.92% | 21.51% | 31.41% |
| Income Tax Expenses | -- | 103.85% | -- | -- | -- |
| Earnings from Continuing Operations | -148.87% | -388.02% | -4.70% | 21.55% | 31.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.84% | -25.00% | -17.65% | -8.70% | -5.00% |
| Net Income | -148.91% | -388.08% | -4.70% | 21.55% | 31.22% |
| EBIT | 13.45% | -8.32% | 6.80% | 30.68% | 28.24% |
| EBITDA | 15.01% | -7.94% | 6.66% | 31.82% | 28.99% |
| EPS Basic | -110.56% | -305.39% | 22.43% | 42.37% | 46.81% |
| Normalized Basic EPS | -111.25% | -300.21% | 21.44% | 42.34% | 46.98% |
| EPS Diluted | -110.56% | -305.39% | 32.05% | 50.56% | 47.90% |
| Normalized Diluted EPS | -111.25% | -300.21% | 21.29% | 42.19% | 46.98% |
| Average Basic Shares Outstanding | 18.22% | 20.36% | 34.98% | 36.03% | 29.30% |
| Average Diluted Shares Outstanding | 18.22% | 20.36% | 34.73% | 35.62% | 29.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |